Literature DB >> 16059488

A promising genetic approach for the treatment of epilepsy.

Robyn Wallace.   

Abstract

Entities:  

Year:  2004        PMID： 16059488      PMCID： PMC1176360          DOI： 10.1111/j.1535-7597.2004.44017.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  7 in total

1.  Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease.

Authors:  R A Steiner; J G Hohmann; A Holmes; C C Wrenn; G Cadd; A Juréus; D K Clifton; M Luo; M Gutshall; S Y Ma; E J Mufson; J N Crawley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 2.  Patients with refractory seizures.

Authors:  O Devinsky
Journal:  N Engl J Med       Date:  1999-05-20       Impact factor: 91.245

3.  Modulation of hippocampal excitability and seizures by galanin.

Authors:  A M Mazarati; J G Hohmann; A Bacon; H Liu; R Sankar; R A Steiner; D Wynick; C G Wasterlain
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

4.  Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus.

Authors:  S Zini; M P Roisin; U Langel; T Bartfai; Y Ben-Ari
Journal:  Eur J Pharmacol       Date:  1993-03-15       Impact factor: 4.432

5.  Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

Authors:  A M Mazarati; H Liu; U Soomets; R Sankar; D Shin; H Katsumori; U Langel; C G Wasterlain
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

6.  Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion.

Authors:  Rebecca P Haberman; R Jude Samulski; Thomas J McCown
Journal:  Nat Med       Date:  2003-07-13       Impact factor: 53.440

7.  Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development.

Authors:  En-Ju D Lin; Cristina Richichi; Deborah Young; Kristin Baer; Annamaria Vezzani; Matthew J During
Journal:  Eur J Neurosci       Date:  2003-10       Impact factor: 3.386
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.